NCT04591106

Brief Summary

Magnetic resonance imaging (MRI) is used to measure liver fat content and fatty tissues in the body, and magnetic resonance elastography (MRE) is used to measure liver stiffness. The information from MRI and MRE are used to understand risk factors and diagnose liver diseases, such as fatty liver disease and liver fibrosis. However, current MRI and MRE scans need to be performed during a breath-hold, which may be challenging or impossible in children and infants. The goal of this research project is to develop and evaluate new free-breathing MRI and MRE technology to improve the comfort and diagnostic accuracy for children and infants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
135

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 13, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 19, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

February 17, 2021

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2026

Completed
Last Updated

March 10, 2026

Status Verified

March 1, 2026

Enrollment Period

5 years

First QC Date

October 13, 2020

Last Update Submit

March 6, 2026

Conditions

Keywords

MRIpediatricliverfibrosis

Outcome Measures

Primary Outcomes (3)

  • Liver Proton Density Fat Fraction (PDFF) by MRI

    Liver proton density fat fraction (PDFF; 0 to 100%) is an MRI based measurement of liver fat content. The liver PDFF measured by the new free-breathing MRI technique will be compared with standard breath-holding MRI in terms of the concordance correlation coefficient. The repeatability of liver PDFF will be measured in terms of the coefficient of variation between two scans. In addition, the diagnostic performance of MRI liver PDFF to detect liver fat will be validated against liver biopsy.

    4 years

  • Abdominal Visceral Adipose Tissue (VAT) Volume by MRI

    Visceral adipose tissue (VAT) volume (cm3) in the abdomen is an MRI based measurement of body composition. The VAT volume measured by the new free-breathing MRI technique will be compared with standard breath-holding MRI in terms of the concordance correlation coefficient. The repeatability of VAT volume will be measured in terms of the coefficient of variation between two scans.

    4 years

  • Liver Tissue Stiffness by MRE

    Liver tissue stiffness (kPa) measured by MRE correlates with liver fibrosis. The liver tissue stiffness measured by the new free-breathing MRE technique will be compared with standard breath-holding MRE in terms of the concordance correlation coefficient. The repeatability of liver tissue stiffness will be measured in terms of the coefficient of variation between two scans. In addition, the diagnostic performance of MRE liver tissue stiffness to detect liver fibrosis will be validated against liver biopsy.

    4 years

Study Arms (3)

Group 1

50 healthy subjects and 50 subjects with NAFLD between ages of 6-17 years old. Each subject will receive 1 MRI/MRE exam. The MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.

Diagnostic Test: Magnetic resonance imaging (MRI)Diagnostic Test: Magnetic resonance elastography (MRE)Device: Prototype MRE soft flexible passive transducer paddle

Group 2

60 subjects with Liver Disease and Fibrosis between ages of 1 month - 40 years old. Each subject will receive 1 MRI/MRE exam. The MRE portion will be performed by placing a paddle on the belly that will produce gentle vibrations.

Diagnostic Test: Magnetic resonance imaging (MRI)Diagnostic Test: Magnetic resonance elastography (MRE)Device: Prototype MRE soft flexible passive transducer paddle

Group 3

15 healthy infants between 1 week - 6 months old and their mothers; 15 at-risk infants (mother had gestational diabetes) between 1 week - 6 months old and their mothers. Each infant will receive 1 MRI scan.

Diagnostic Test: Magnetic resonance imaging (MRI)

Interventions

Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Group 1Group 2Group 3

Magnetic resonance elastography (MRE) is a non-invasive imaging technique that uses a gently vibrating transducer in combination with MRI to create detailed images and maps of the mechanical properties, such as stiffness, of tissues within the body.

Group 1Group 2

The prototype device is provided to the investigators by Mayo Clinic under a Materials Transfer Agreement (MTA). The device is being used to promote comfort in the pediatric population; no formal data collection for regulatory submission is planned. The prototype device is smaller, softer, and more flexible than the commercial device and will be used where indicated by the subjects' size.

Also known as: MRE transducer paddle
Group 1Group 2

Eligibility Criteria

Age1 Week - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Study 1 (Aim 1 and Aim 2): 50 healthy subjects 6-17 years old, 50 subjects with NAFLD 6-17 years old; Study 2 (Aim 3): 60 subjects with Liver Disease and Fibrosis 1 month-40 years old; Study 3 (Aim 4): Study 3 (Aim 4): 15 Pairs of Healthy Infants (1 week-6 months old) and their Mothers. 15 Pairs of Infants (1 week-6 months old) born to Mothers with Gestational Diabetes and their Mothers.

You may not qualify if:

  • Study 1 (Aim 1 and Aim 2):
  • years of age
  • BMI \>85th percentile
  • diagnosed or clinically suspected to have NAFLD (NAFLD or suspected NAFLD is defined as serum alanine transaminase concentration \>30 IU/L in the appropriate clinical setting)
  • ability to follow instructions and perform short breath holds
  • years of age
  • body mass index \<85th percentile
  • ability to follow instructions and perform short breath holds
  • known liver disease (except for NAFLD/NASH for the NAFLD cohort)
  • congenital malformation
  • inborn error of metabolism
  • contraindications to MRI
  • inability to perform breath-holding
  • Study 2 (Aim 3):
  • children and adults 1 month-40 years of age
  • +19 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCLA Medical Center

Los Angeles, California, 90095, United States

Location

MeSH Terms

Conditions

Non-alcoholic Fatty Liver DiseaseFibrosis

Interventions

Magnetic Resonance ImagingElasticity Imaging Techniques

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

TomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisUltrasonography

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 13, 2020

First Posted

October 19, 2020

Study Start

February 17, 2021

Primary Completion

February 28, 2026

Study Completion

February 28, 2026

Last Updated

March 10, 2026

Record last verified: 2026-03

Locations